Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Revenue (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Revenue data on record, last reported at $148.9 million in Q4 2025.

  • For Q4 2025, Revenue rose 49.81% year-over-year to $148.9 million; the TTM value through Dec 2025 reached $521.3 million, up 54.74%, while the annual FY2025 figure was $521.3 million, 54.74% up from the prior year.
  • Revenue reached $148.9 million in Q4 2025 per MIRM's latest filing, up from $133.0 million in the prior quarter.
  • Across five years, Revenue topped out at $148.9 million in Q4 2025 and bottomed at $3.1 million in Q4 2021.
  • Average Revenue over 5 years is $60.0 million, with a median of $47.7 million recorded in 2023.
  • Peak YoY movement for Revenue: skyrocketed 789.29% in 2022, then surged 42.93% in 2024.
  • A 5-year view of Revenue shows it stood at $3.1 million in 2021, then soared by 789.29% to $27.9 million in 2022, then soared by 149.24% to $69.6 million in 2023, then soared by 42.93% to $99.4 million in 2024, then surged by 49.81% to $148.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $148.9 million in Q4 2025, $133.0 million in Q3 2025, and $127.8 million in Q2 2025.